Beghetti Maurice, Galiè Nazzareno, Bonnet Damien
Pediatric Cardiology Unit, Department of the Child and Adolescent, Children's University Hospital, 6 Rue Willy Donzé, Geneva, Switzerland.
Congenit Heart Dis. 2012 Jan-Feb;7(1):3-11. doi: 10.1111/j.1747-0803.2011.00611.x. Epub 2012 Jan 10.
The decision whether to repair congenital heart defects in patients with raised pulmonary vascular resistance to alleviate pulmonary hypertension is a complex one. The degree of pulmonary vascular disease is of paramount importance. Operating on patients with pulmonary vascular resistance above a certain threshold runs the risk of postoperative persistent pulmonary hypertension and a worse long-term prognosis. This review focuses on patients deemed "borderline inoperable" or "inoperable" due to pulmonary vascular disease and asks whether they can be "converted to an operable status" with pulmonary arterial hypertension-specific drugs that potentially modify the pulmonary vascular lesions and resistance.
对于患有肺动脉高压且肺血管阻力升高的患者,决定是否修复先天性心脏缺陷是一个复杂的问题。肺血管疾病的程度至关重要。对肺血管阻力高于特定阈值的患者进行手术,有术后持续性肺动脉高压和长期预后较差的风险。本综述聚焦于因肺血管疾病被认为“手术边缘不可行”或“不可行”的患者,并探讨他们是否可以通过使用可能改变肺血管病变和阻力的肺动脉高压特异性药物“转变为可手术状态”。